Protocols
12 protocol(s) meet the specified criteria
Disease Site: Melanoma, Skin
Protocol No.TitleStatus
APEC1621SCNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)Open
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
INCAGN1876-201A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination with Immune therapies in Subjects with Advanced or Metastatic MalignanciesOpen
LCCC0824Tissue Procurement For Hematolymphoid ConditionsOpen
LCCC1531Pembrolizumab in Systemic Treatment-Naïve Distant Metastatic Melanoma and Exploration of use of 11Cmethyl-L-tryptophan (AMT) PET at Baseline as a Predictive Imaging Biomarker of ResponseOpen
LCCC1734Adaptation of the Parenting Concerns Questionnaire for Patients with IllnessOpen
LCCC1802Randomized Trial of Parotid Sparing Whole Brain RadiationOpen
LCCC1805Pediatric Oncology Tissue Procurement to Support Research on Molecular Drivers and Precision Medicine ApproachesOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NC-6300-001A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue SarcomaOpen
S1616-CIRBA Phase II Randomized Study of Nivolumab (NSC-732442) With Ipilimumab (NSC-748726) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 AgentOpen